Moshang T, Rundle A C, Graves D A, Nickas J, Johanson A, Meadows A
Division of Endocrinology, Children's Hospital of Philadelphia, PA 19104, USA.
J Pediatr. 1996 May;128(5 Pt 2):S4-7. doi: 10.1016/s0022-3476(96)70002-1.
As of October 1993 the National Cooperative Growth Study included 1262 children with brain tumor who were treated with growth hormone. The type of brain tumor was specified in 947 (75%) of these children. The most common types were glioma, medulloblastoma, and craniopharyngioma, accounting for 91.3% of all those for which type was specified. Brain tumor recurred in 83 (6.6%) of the 1262 children over a total of 6115 patient-years at risk. The frequencies of tumor recurrence in children with low-grade glioma (18.1%), medulloblastoma (7.2%), and craniopharyngioma (6.4%) are lower than those in published reports of tumor recurrence in the general pediatric population with the same types of tumors. The analysis cannot conclusively show that no increased risk of tumor recurrence exists, however, because of the potential incompleteness of data reporting in the National Cooperative Growth Study. Nevertheless the findings are reassuring that children with the more common types of brain tumor who are treated with growth hormone do not seem to be at excessive risk for tumor recurrence.
截至1993年10月，全国合作生长研究纳入了1262例接受生长激素治疗的脑肿瘤患儿。其中947例（75%）患儿明确了脑肿瘤类型。最常见的类型是胶质瘤、髓母细胞瘤和颅咽管瘤，占所有明确类型的91.3%。在1262例患儿中，共有6115患者年的风险期，其中83例（6.6%）脑肿瘤复发。低级别胶质瘤患儿（18.1%）、髓母细胞瘤患儿（7.2%）和颅咽管瘤患儿（6.4%）的肿瘤复发频率低于已发表的同类型肿瘤的普通儿科人群肿瘤复发报告中的频率。然而，由于全国合作生长研究中数据报告可能不完整，该分析不能确凿地表明不存在肿瘤复发风险增加的情况。尽管如此，这些发现令人安心，即接受生长激素治疗的较常见类型脑肿瘤患儿似乎不存在过高的肿瘤复发风险。
